The Endothelial Spectrum: Vascular Tumors and Developmental Malformations
Vascular anomalies are notoriously difficult to classify. A red, growing mass on an infant could be a rapidly involuting, benign infantile hemangioma, or it could be the first sign of a lethal, deep-tissue angiosarcoma. The historical terminology (e.g., calling everything a “cavernous hemangioma”) is chaotic and dangerous. Vascular Tumors and Developmental Malformations: Pathogenic Mechanisms and Molecular Diagnosis is a fiercely specialized, paradigm-shifting text designed to impose order on this chaos. This volume provides the exact blueprints required to classify vascular lesions based on their true underlying genetic and molecular drivers.
Mastering the ISSVA Classification
The core philosophy of this text is the strict adherence to the International Society for the Study of Vascular Anomalies (ISSVA) classification system. The authors aggressively detail the fundamental biological difference between true *vascular tumors* (driven by endothelial cell proliferation and specific mutations, like infantile hemangiomas) and *vascular malformations* (static architectural defects in capillaries, veins, or lymphatics driven by germline or somatic mutations, like PIK3CA).
Navigating Hemangioendotheliomas and Angiosarcomas
The book provides a masterclass in vascular oncology. It dictates the exact diagnostic pathways for the treacherous “intermediate” vascular tumors (like epithelioid hemangioendothelioma), which often lack aggressive morphological features but can metastasize and kill. It provides exhaustive reviews of highly lethal angiosarcomas, detailing the distinct molecular pathways of radiation-induced versus primary angiosarcomas.
Frequently Asked Questions (FAQs)
Does this book cover targeted therapies for vascular anomalies?
Yes, it rigorously links specific genetic mutations (like the mTOR pathway) to emerging medical therapies (like sirolimus), which are revolutionizing the treatment of massive, un-resectable vascular malformations.
Who is the primary audience?
It is the absolute, mandatory reference for Soft Tissue Pathologists, Pediatric Surgeons, Dermatologists, and Interventional Radiologists treating these lesions.
